|
Characteristic
|
No PFT abnormalities (n = 114)
|
PFT abnormalities (n = 45)
|
P value
|
|---|
|
Age (years)
|
61 ± 7.7
|
63 ± 9.9
|
0.14
|
|
Male gender
|
41 (36)
|
21 (47)
|
0.21
|
|
Caucasian
|
99 (87)
|
37 (82)
|
0.46
|
|
Body mass index (kg/m2)
|
29 ± 5.0
|
28 ± 5.5
|
0.12
|
|
Ever smoker
|
63 (55)
|
29 (64)
|
0.29
|
|
Current smoker
|
9 (7.9)
|
10 (22)
|
0.012
|
|
Reported lung disease
|
13 (11)
|
17 (38)
|
< 0.001
|
|
Emphysema
|
2 (1.8)
|
8 (18)
|
< 0.001
|
|
Asthma
|
12 (11)
|
8 (18)
|
0.22
|
|
Rheumatoid lung disease
|
0 (0)
|
2 (4.7)
|
0.07
|
|
CAC > 100
|
34 (30)
|
19 (42)
|
0.14
|
|
RA characteristics
| | | |
|
RA duration (years)
|
9.9 (5.6 to 18)
|
11 (7.1 to 23)
|
0.16
|
|
RF seropositive
|
64 (56)
|
35 (78)
|
0.011
|
|
Anti-CCP seropositive
|
67 (59)
|
37 (84)
|
0.003
|
|
DAS28 (units)
|
3.1 (2.4 to 3.7)
|
3.1 (2.4 to 4.2)
|
0.74
|
|
HAQ (units)
|
0.75 (0.13 to 1.5)
|
0.88 (0.13 to 1.5)
|
0.48
|
|
Modified Sharp Score (units)
|
41 (12 to 99)
|
56 (25 to 140)
|
0.098
|
|
Current prednisone
|
35 (31)
|
23 (51)
|
0.018
|
|
Current nonbiologic DMARDs
|
99 (88)
|
38 (84)
|
0.60
|
|
Current biologic DMARDs
|
55 (49)
|
20 (44)
|
0.63
|
|
Reported pulmonary symptoms
| | | |
|
Any reported symptoms
|
41 (36)
|
26 (58)
|
0.012
|
|
Any cough
|
19 (17)
|
16 (36)
|
0.010
|
|
Any phlegm
|
22 (19)
|
16 (36)
|
0.030
|
|
Any wheezing
|
17 (15)
|
18 (42)
|
0.001
|
|
Any breathlessness
|
18 (16)
|
15 (33)
|
0.014
|
- Data expressed as mean ± standard deviation, n (%) or median (interquartile range). CAC, coronary artery calcium; CCP, cyclic citrullinated peptide; DAS28, RA Disease Activity Score in 28 joints; DMARDs, disease-modifying antirheumatic drugs; PFT, pulmonary function test; RA, rheumatoid arthritis; RF, rheumatoid factor.
